Top

Published in:

01-07-2009 | Original Article

Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study

Authors: Kyung Hee Lee, Min Kyoung Kim, Yeol Hong Kim, Baek Yeol Ryoo, Ho Yeong Lim, Hong Suk Song, Hoon Kyo Kim, Myung Ah Lee, Seock Ah Im, Heung Moon Chang, Jae Yong Cho, Dae Young Zang, Bong Seog Kim, Jun Suk Kim

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2009

Abstract

Purpose

Gemcitabine is the only drug approved for single-agent therapy in advanced pancreatic carcinoma (APC). Gemcitabine-based combination chemotherapy has not yet shown promising results.

Methods

This multicenter phase II study enrolled previously untreated patients with locally advanced and/or metastatic pancreatic adenocarcinoma. Patients received 1,000 mg/m² gemcitabine, 100-min infusion, day 1 and 100 mg/m² oxaliplatin, 2-h infusion, day 2; q2w. The primary end point was response rate (RR).

Results

Thirteen study centers enrolled 48 eligible patients of which 44 were evaluable. The RR, median overall survival, and median time to progression were 18.2%, 9.4 and 5.6 months, respectively. Sixteen patients (36.4%) experienced clinical benefit. The global quality of life scores improved by 11.71. Grade 3/4 peripheral sensory neuropathy was noted (2.1%), while the most common hematologic toxicity was anemia (grade 3/4, 6.3%).

Conclusions

Gemcitabine and oxaliplatin combination chemotherapy showed a promising activity in APC patients and was well tolerated.

Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMed

Van Cutsem E, Aerts R, Haustermans K et al (2004) Systemic treatment of pancreatic cancer. Eur J Gastroenterol Hepatol 16:265–274PubMedCrossRef

Rao S, Cunningham D (2002) Advanced pancreatic cancer–5 years on. Ann Oncol 13:1165–1168PubMedCrossRef

O’Reilly E, Abou-Alfa G (2007) Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 34:347–353PubMedCrossRef

Yoon SY, Park KH, Oh SC et al (2002) Phase II trial of gemcitabine, UFT-E, leucovorin combination chemotherapy in advanced pancreatic adenocarcinoma. Cancer Res Treat 34:111–116

Peters GJ, Bergman AM, Ruiz van Haperen VW et al (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22(suppl 11):72–79PubMed

Cvitkovic E (1998) Ongoing and unsaid on oxaliplatin: the hope. Br J Cancer 77(suppl 4):8–11PubMed

Heinemann V, Quietzsch D, Gieseler F et al. (2001) Gemcitabine plus cisplatin versus gemcitabine in advanced pancreatic cancer: preliminary results of a randomized phase III trial. Proc Am Soc Clin Oncol 20 (abstract 625)

Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509–3516PubMedCrossRef

10.

Woynarowski JM, Chapman W et al (1996) Mechanism of action of oxaliplatin, specificity of adduct formation. San Antonio, Texas

11.

Woynarowski JM, Chapman W, Napier C et al (1997) Mechanisms of action of oxaliplatin:oxaliplatin-induced lesions in cellular DNA. San Antonio, Texas

12.

Boudný V, Vrána O, Gaucheron F et al (1992) Biophysical analysis of DNA modified by 1, 2-diaminocyclohexane platinum(II) complexes. Nucleic Acids Res 20:267–272PubMedCrossRef

13.

Mamenta EL, Poma EE, Kaufmann WK et al (1994) Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 54:3500–3505PubMed

14.

Aebi S, Kurdi-Haidar B, Gordon R et al (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56:3087–3090PubMed

15.

Fink D, Zheng H, Nebel S et al (1997) In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57:1841–1845PubMed

16.

Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9:1053–1071PubMedCrossRef

17.

Kornmann M, Fakler H, Butzer U, Beger HG, Link KH (2000) Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. Anticancer Res 20:3259–3264PubMed

18.

Rothenberg ML, Moore MJ, Cripps MC et al (1996) A phase II trial of gemcitabine in patients with 5 FU-refractory pancreas cancer. Ann Oncol 7:347–353PubMed

19.

Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C 30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef

20.

Glimelius B, Hoffman K, Sjödén PO et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593–600PubMed

21.

Fitzsimmons D, Johnson CD, George S et al (1999) Development of disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. Eur J Cancer 35:939–941PubMedCrossRef

22.

Fleming TR (1982) One-sample multiple testing procedures for phase II clinical trials. Biometrics 38:143–151PubMedCrossRef

23.

Lee KU, Kim ID, Kim JC, Kim JP (1989) Prognostic factors and adequate surgical management of pancreatic cancer-clinical analysis of 12 years from 1976–1987. Korean J Gastroenterol 21:404–413

24.

Lee SJ, Lee YC, Song SY et al (1994) Clinical study on pancreatic cancer and its prognostic factors. Korean J Gastroenterol 26:1010–1020

25.

Min YJ, Joo KR, Park NH et al (2002) Gemcitabine therapy in patients with advanced pancreatic cancer. Korean J Int Med 17:259–262

26.

Jung SW, Park JY, Kim YS et al (2005) Survival analysis according to treatment modality in pancreatic cancer patients. Korean J Gastroenterol 46:120–128 (in Korean)PubMed

27.

Park JK, Yoon YB, Kim YT et al (2007) Survival and prognostic factors of unresectable pancreatic cancer. Korean J Med 72:151–161

28.

Oettle H, Arnold D, Hempel C, Riess H (2000) The role of gemcitabine alone and in combination in the treatment of pancreatic cancer. Anticancer Drugs 11:771–786PubMedCrossRef

29.

Xie DR, Liang HL, Wang Y, Guo SS, Yang Q (2006) Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone. World J Gastroenterol 12:6973–6981PubMed

30.

Louvet C, André T, Lledo G et al (2002) Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 20:1512–1518PubMedCrossRef

31.

Poplin E, Levy DE, Berlin J et al (2006) Phase III trial of gemcitabine (30 minute infusion) vs gemcitabine (fixed dose-rate infusion [FDR]) vs gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer. Proc Am Clin Oncol 26:180s (abstract 4004)

32.

Alberts SR, Townley PM, Goldberg RM et al (2003) Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Ann Oncol 14:580–585PubMedCrossRef

33.

Mavroudis D, Kourousis C, Kakolyris S et al (2000) Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report. Semin Oncol 27(Suppl 2):25–30PubMed

34.

Shibata S, Chow W, Frankel P et al (2001) A phase I trial of oxaliplatin (OX) in combination with gemcitabine (G): a California Consortium trial. Proc Am Soc Clin Oncol 20:96a (abstract 381)

35.

Faivre S, Raymond E, Lokiec F et al (2001) Final results of the phase I–II and pharmacokinetic study GEM/OX combining gemcitabine (Gem) with oxaliplatin (Ox) in patients (pts) with advanced non-small-cell lung (NSCLC) and ovarian carcinoma (OC). Proc Am Soc Clin Oncol 20:89b (abstract 2105)

36.

Airoldi M, Cattel L, Passera R et al (2006) Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data. Pancreas 32:44–50PubMedCrossRef

37.

Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W (1991) Saturation of 2′, 2′-difluorodeoxycytidine 5’-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27:258–262PubMedCrossRef

38.

Gandhi V, Plunkett W, Du M, Ayres M, Estey EH (2002) Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 20:665–673PubMedCrossRef

39.

Tempero M, Plunkett W, Ruiz van Haperen V (1999) Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 18:273a (abstract 1048)

40.

Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 356:125–134PubMedCrossRef

41.

Gradishar W, Drasnojon D, Cheporov S et al. (2007) Randomized comparison of weekly or every 3-week nab-paclitaxel compared to q3w docetaxel as first line therapy in patients with metastatic breast cancer. J Clin Oncol 25(18S) (abstract 1032)

42.

Bramhall SR, Schulz J, Nemunaitis J et al (2002) A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161–167PubMedCrossRef

43.

Moore MJ, Hamm J, Dancey J et al (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12–9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 21:3296–3302PubMedCrossRef

44.

Conroy T, Paillot B, François E et al (2005) Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-A Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre Le Cancer Study. J Clin Oncol 23:1228–1236PubMedCrossRef

Title: Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
Authors: Kyung Hee Lee
Min Kyoung Kim
Yeol Hong Kim
Baek Yeol Ryoo
Ho Yeong Lim
Hong Suk Song
Hoon Kyo Kim
Myung Ah Lee
Seock Ah Im
Heung Moon Chang
Jae Yong Cho
Dae Young Zang
Bong Seog Kim
Jun Suk Kim
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0873-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2009

Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro

Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours

The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells

Protein nitration, PARP activation and NAD+ depletion may play a critical role in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis in the rat

Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer